SLC5A2 and diabetes mellitus: Structurally, SGLT2-i therapy leads to favorable LVR: in patients with diabetes or prediabetes and reduced LVEF, empagliflozin produced greater reductions in LV volumes than placebo [182], and dapagliflozin showed similar results even in non-diabetic patients [183].